Poseida Therapeutics, Inc. (PSTX)
Jan 8, 2025 - PSTX was delisted (reason: acquired by Roche)
9.50
0.00 (0.00%)
Inactive · Last trade price on Jan 7, 2025
Poseida Therapeutics Revenue
Poseida Therapeutics had revenue of $71.75M in the quarter ending September 30, 2024, with 667.19% growth. This brings the company's revenue in the last twelve months to $150.86M, up 203.18% year-over-year. In the year 2023, Poseida Therapeutics had annual revenue of $64.70M, down -50.42%.
Revenue (ttm)
$150.86M
Revenue Growth
+203.18%
P/S Ratio
6.08
Revenue / Employee
$457,145
Employees
330
Market Cap
928.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 64.70M | -65.79M | -50.42% |
| Dec 31, 2022 | 130.49M | 99.25M | 317.73% |
| Dec 31, 2021 | 31.24M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPSTX News
- 3 months ago - Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company - GlobeNewsWire
- 10 months ago - Roche to complete acquisition of U.S. biopharma company Poseida - Reuters
- 11 months ago - Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting - PRNewsWire
- 11 months ago - POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX - Business Wire
- 11 months ago - Poseida shares triple on Tuesday, boosted by Roche collaboration - Invezz
- 11 months ago - Why This Gene-Therapy Company's Stock Is Rising 228% - Barrons
- 11 months ago - Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details - Benzinga
- 1 year ago - Roche to acquire US-based Poseida Therapeutics - Reuters